AISA Pharma Announces Positive Data Safety Monitoring Board Review of First Phase 2 Data of Profervia® to treat Raynaud’s Disease in Scleroderma Patients
26 juil. 2022 17h50 HE
|
Aisa Pharma, Inc.
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, today announced that the Data Safety Monitoring Board (DSMB) for the...